Abstract
ObjectiveTo assess whether a novel ‘direct access pathway’ (DAP) for the management of high-risk non-ST-elevation acute coronary syndromes (NSTEACS) is safe, results in ‘shorter time to intervention and shorter admission...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have